The lowest relapse and discontinuation rates were observed after switching from Natalizumab to Ocrelizumab.

Published Date: 29 Jun 2023

Compared to ocrelizumab, using fingolimod was linked to a 49 percent higher risk of disability accumulation, in addition to higher relapse rates.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

2.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

3.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

4.

Ketamine plus psychotherapy for "excellent" PTSD

5.

No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot